Geodesic
Mathematical modeling of cancer treatment
Vestnik Sankt-Peterburgskogo universiteta. Prikladnaâ matematika, informatika, processy upravleniâ, Tome 16 (2020) no. 4, pp. 437-446
Cet article a éte moissonné depuis la source Math-Net.Ru

Voir la notice de l'article

The paper proposes mathematical models of ovarian neoplasms. The models are based on a mathematical model of interference competition. Two types of cells are involved in the competition for functional space: normal and tumor cells. The mathematical interpretation of the models is the Cauchy problem for a system of ordinary differential equations. The dynamics of tumor growth is determined on the basis of the model. A model for the distribution of conditional patients according to four stages of the disease, a model for assessing survival times for groups of conditional patients, and a chemotherapy model are also proposed.
Keywords: differential equations, mathematical modeling, neoplasms, ovarian cancer, morbidity, treatment, statistics. 
@article{VSPUI_2020_16_4_a7,
     author = {A. B. Goncharova and E. P. Kolpak and M. M. Rasulova and A. V. Abramova},
     title = {Mathematical modeling of cancer treatment},
     journal = {Vestnik Sankt-Peterburgskogo universiteta. Prikladna\^a matematika, informatika, processy upravleni\^a},
     pages = {437--446},
     year = {2020},
     volume = {16},
     number = {4},
     language = {ru},
     url = {http://geodesic.mathdoc.fr/item/VSPUI_2020_16_4_a7/}
}
TY  - JOUR
AU  - A. B. Goncharova
AU  - E. P. Kolpak
AU  - M. M. Rasulova
AU  - A. V. Abramova
TI  - Mathematical modeling of cancer treatment
JO  - Vestnik Sankt-Peterburgskogo universiteta. Prikladnaâ matematika, informatika, processy upravleniâ
PY  - 2020
SP  - 437
EP  - 446
VL  - 16
IS  - 4
UR  - http://geodesic.mathdoc.fr/item/VSPUI_2020_16_4_a7/
LA  - ru
ID  - VSPUI_2020_16_4_a7
ER  - 
%0 Journal Article
%A A. B. Goncharova
%A E. P. Kolpak
%A M. M. Rasulova
%A A. V. Abramova
%T Mathematical modeling of cancer treatment
%J Vestnik Sankt-Peterburgskogo universiteta. Prikladnaâ matematika, informatika, processy upravleniâ
%D 2020
%P 437-446
%V 16
%N 4
%U http://geodesic.mathdoc.fr/item/VSPUI_2020_16_4_a7/
%G ru
%F VSPUI_2020_16_4_a7
A. B. Goncharova; E. P. Kolpak; M. M. Rasulova; A. V. Abramova. Mathematical modeling of cancer treatment. Vestnik Sankt-Peterburgskogo universiteta. Prikladnaâ matematika, informatika, processy upravleniâ, Tome 16 (2020) no. 4, pp. 437-446. http://geodesic.mathdoc.fr/item/VSPUI_2020_16_4_a7/

[1] V. Ryazhenov, S. G. Gorokhova, K. I. Zhordania, Y. G. Payanidi, N. D. Bunyatyan, “Clinical and statistical analysis of ovarian cancer incidence rate and identification of a subgroup of patients with BRCA1/2 mutations in the Russian Federation”, Journal of Pharmaceutical Sciences and Research, 2018, no. 10, 2500–2502

[2] M. A. Chaplain, J. A. Sherratt, “A new mathematical model for avascular tumor growth”, Journal of Mathematical Biology, 43:4 (2000), 291–312 | MR

[3] E. P. Kolpak, R. T. Abuzyarova, S. A. Kabrits, “Leukosis mathematical model”, Asian Journal of Pharmaceutics, 2018, no. 1, S340–S345

[4] M. B. Kuznetsov, A. V. Kolobov, “Influence of chemotherapy on progression of biclonal tumor Analysis by means of mathematical modeling”, Biophysics (Russian Federation), 64:2 (2019), 279–292 | DOI

[5] E. P. Kolpak, I. S. Frantsuzova, K. V. Kuvshinova, R. E. Senkov, “Neoplasm morbidity among the population of Russia”, Intern. Journal of Advanced Biotechnology and Research, 8:3 (2017), 2315–2322

[6] Merabishvili V. M., Oncological statistics (traditional methods, new information technologies), Guidelines for physicians, Printing company KOSTA Publ., Saint Petersburg, 2015, 223 pp. (In Russian)

[7] P. T. Kroeger, R. Drapkin, “Pathogenesis and heterogeneity of ovarian cancer”, Curr Opin Obstet Gynecol, 29:1 (2017), 26–34 | DOI

[8] A. M. Karst, R. Drapkin, “Ovarian cancer pathogenesis: a model in evolution”, Molecular genetic markers in female reproductive cancers, 2010, Special Issue, 932371, 13 pp. | DOI

[9] A. F. Urmancheeva, “Chemotherapy for recurrent ovarian cancer (literature review)”, Scientific and practical reviewed journal. Siberian Journal of Oncology, 3(39) (2010), 28–33

[10] A. M. Beishembaev, K. I. Zhordania, “Clinical and histological features of purely stromal cell ovarian tumors”, Obstetrics, Gynecology and Reproduction, 13:4 (2019), 289–296 | DOI

[11] E. S. Bamberger, C. W. Perrett, “Angiogenesis in epithelian ovarian cancer”, Mol. Pathol., 55:6 (2002), 348–359 | DOI

[12] M. Devouassoux-Shisheboran, C. Genestie, “Pathobiology of ovarian carcinomas”, Chinese Journal of Cancer, 34:1 (2015), 50–55 | DOI

[13] Limei Wang, Xiaoyan Liu, Hong Wang, Shuhe Wang, “Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer”, Oncology Letters, 15 (2013), 175–180 | DOI

[14] E. S. Gershtein, D. N. Kushlinsky, N. V. Levkina, I. V. Tereshkina, V. B. Nosov, K. P. Laktionov, L. V. Adamyan, “Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumors”, Bulletin of Experimental Biology and Medicine, 151:4 (2011), 449–453 | DOI

[15] T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin, B. E. Polotsky, M. M. Davydov, “The quantitative indices of ERCC1 expression in serous ovarian cancer tissue and the efficacy of first-line platinum-based chemotherapy”, Antibiotics and Chemotherapy, 63:1–2 (2018), 24–31

[16] Khokhlova S. V., Cherkasova M. V., Orel N. F., Limareva S. V., Bazaeva I. A., Gorbunova V. A., “Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin”, Annals of the Russian Academy of Medical Sciences, 68:11 (2013), 115–121 (In Russian) | DOI

[17] L. Gatti, G. L. Beretta, “Ovarian cancer: pathogenesis, diagnosis, and treatment”, Version 1, International Journal of Molecular Sciences, 6:84 (2017), 1–12 | DOI

[18] P. M. Das, R. C. Bast, “Early detection of ovarian cancer”, Biomark Med., 2:3 (2008), 291–303 | DOI

[19] E. Chu, V. T. DeVita, Physicians cancer chemotherapy drug manual, Jones and Bartlett Publ., New York, 2007, 455 pp.

[20] A. M. Belyaev, G. I. Gafton, E. V. Levchenko, A. M. Karachun, A. V. Gulyaev, K. Yu. Senchik, V. G. Bespalov, I. V. Berlev, A. F. Urmancheeva, K. D. Guseinov, Yu. V. Semiletova, O. N. Mamontov, P. V. Kalinin, G. S. Kireeva, O. A. Belyaeva, V. V. Alexeev, “ChemoPerfuSion technologies in treatment for malignant tumors”, Problems in Oncology, 61:3 (2015), 477–485

[21] A. J. Cortez, P. Tudrej, K. A. Kujawa, K. M. Lisowska, “Advances in ovarian cancer therapy”, Cancer Chemother Pharmacol, 81:1 (2018), 17–38 | DOI

[22] The State of Cancer Care Provided to the Population of Russia in 2018, Branch Office of FSBI NMRRC, Ministry of Health of Russia, FSBI P. A. Herzen Moscow Cancer Research Institute, M., 2018, 236 (accessed: May 22, 2020); http://www.oncology.ru/service/statisticshttps://nnood.ru/wp-content/uploads/2019/04/Statichticheskijj-ezhegodnik-Gercena-2018.pdf

[23] V. M. Merabishvili, E. M. Bogdanova, A. F. Urmancheeva, O. F. Chepik, N. R. Safronnikova, E. I. Laliantsi, “Age-related features of morbidity, mortality and morphological verification of ovarian carcinoma”, Problems in Onkology, 56:2 (2010), 144–151

[24] E. M. Aksel, N. N. Vinogradova, “Statistics of malignant neoplasms of female reproductive organs”, Gynecologic Oncology, 2018, no. 3 (27), 64–78

[25] E. P. Kolpak, I. S. Frantsuzova, E. O. Evmenova, “Oncological diseases in St. Petersburg, Russia”, Drug Invention Today, 11:3 (2019), 510–516

[26] R. L. Siegel, K. D. Miller, A. Jemal, “Cancer statistics 2020”, CA: A Cancer Journal Clinicians, 70:1 (2020), 1–30 | DOI